ArticleTherapeutic advances in medical oncology2026
Chemotherapy relative dose intensity and survival outcomes in pediatric and adolescent locoregionally advanced nasopharyngeal carcinoma: A retrospective cohort study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric and adolescent nasopharyngeal carcinoma (pNPC) is a rare malignancy, and contemporary chemotherapy regimens are largely extrapolated from adult protocols. Adult-intensity chemotherapy is often associated with substantial toxicity in younger patients. Whether chemotherapy dose intensity can be safely reduced in children and adolescents with pNPC remains unclear. Objectives: This study aimed to evaluate the association between chemotherapy relative dose intensity (RDI) and survival outcomes in pNPC. Design: This was a single-center retrospective cohort study of pediatric and adolescent patients with locoregionally advanced nasopharyngeal carcinoma treated between 2006 and 2021. Methods: We retrospectively analyzed patients aged ≤21 years with newly diagnosed stage III-IVa (American Joint Committee on Cancer (AJCC) 8th edition) pNPC treated between 2006 and 2021. Relative dose intensity (RDI) of first-line chemotherapy was calculated and categorized as <85% versus ≥85%. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Multivariable Cox regression was used to evaluate the independent prognostic value of RDI and other covariates. Results: A substantial proportion of patients had an RDI <85%. In the overall cohort, RDI <85% was not significantly associated with worse survival outcomes in survival analyses. Pretreatment plasma Epstein-Barr virus (EBV) DNA level was independently associated with worse survival outcomes. In exploratory analyses, among patients with plasma EBV DNA <4000 copies/mL, RDI <85% suggested an association with worse OS (P for interaction=0.025). Conclusions: In pediatric and adolescent nasopharyngeal carcinoma, these findings suggest potential feasibility of dose reduction but require prospective validation. However, maintaining adequate chemotherapy intensity could be particularly important for patients with lower pretreatment plasma EBV DNA level. Pretreatment plasma EBV DNA may serve as a potential biomarker to guide individualized adjustment of chemotherapy dose intensity in pNPC, which warrants validation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.